Owen, Dafydd R.

An oral SARS-CoV-2 M pro inhibitor clinical candidate for the treatment of COVID-19

Owen, D. R., Allerton, C. M. N., Anderson, A. S., Aschenbrenner, L., Avery, M., Berritt, S., Boras, B., Cardin, R. D., Carlo, A., Coffman, K. J., et al. (2021) · Science

SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research Studies

Cited by 2,033

The promise and peril of chemical probes

Arrowsmith, C. H., Audia, J. E., Austin, C., Baell, J., Bennett, J., Blagg, J., Bountra, C., Brennan, P. E., Brown, P. J., Bunnage, M. E., et al. (2015) · Nature Chemical Biology

Click Chemistry and ApplicationsComputational Drug Discovery Methods

Cited by 839

The SMARCA2/4 ATPase Domain Surpasses the Bromodomain as a Drug Target in SWI/SNF-Mutant Cancers: Insights from cDNA Rescue and PFI-3 Inhibitor Studies

Vangamudi, B., Paul, T. A., Shah, P. K., Kost-Alimova, M., Nottebaum, L., Shi, X., Zhan, Y., Leo, E., Mahadeshwar, H. S., Protopopov, A., et al. (2015) · Cancer Research

Chromatin Remodeling and CancerProtein Degradation and Inhibitors

Cited by 281

Discovery of a Novel Inhibitor of Coronavirus 3CL Protease for the Potential Treatment of COVID-19

Boras, B., Jones, R. M., Anson, B. J., Arenson, D., Aschenbrenner, L., Bakowski, M. A., Beutler, N., Binder, J., Chen, E., Eng, H., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory)

SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research Studies

Cited by 154